Hong-Ping Yao

In vivo CAR T-cell generation: delivery platforms, clinical progress, and translational barriers

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of several hematological malignancies, but its broader application remains constrained by the complexity, cost, and time required for conventional ex vivo manufacturing. In vivo CAR T-cell therapy has emerged as a promising next-generation str...